Pharmaceutical Executive
IN OUR APRIL 2006 ISSUE, we will explore the results of a reader study—a" pulse check" as we think of it—on the topics of promotional programs, meeting spend, and compliance, cosponsored by Maritz Travel and Pharmaceutical Executive. The study asked industry leaders about their perceptions of their companies' physician meetings in terms of audience, format, and budget, as well as their views on compliance regulations.
IN OUR APRIL 2006 ISSUE, we will explore the results of a reader study—a" pulse check" as we think of it—on the topics of promotional programs, meeting spend, and compliance, cosponsored by Maritz Travel and Pharmaceutical Executive. The study asked industry leaders about their perceptions of their companies' physician meetings in terms of audience, format, and budget, as well as their views on compliance regulations. A total of 61 readers involved in compliance monitoring or management of promotional program budgets within the pharmaceutical industry responded.
Because of the small sample and non-scientific nature of the sampling, the results may not be representative of all Pharm Exec readers. Findings are more qualitative than quantitative, but they help to tell a story even without providing significant statistics. They begin to provide a picture of what your fellow industry executives believe.
Some Highlights Include:
In-person meetings and one-on-one sales calls are the most commonly used meeting formats. Respondents reported that these meeting formats are most effective for conveying product information and gaining strong physician participation.
Many respondents feel that their company is doing only an average job of reaching the right audience and getting a good turnout for their promotional meetings, so there is still much room for improvement.
In general, study respondents feel that pharma companies have taken recent changes in compliance regulations very seriously.
• Two-thirds of respondents agree that the pharma industry is strictly following compliance regulations.
• Respondents report having dedicated compliance departments and legal departments to handle issues related to compliance requests.
On average, companies received 24 compliance requests during the past year; three out of five came from a state, and the rest from federal agencies.
Stay tuned for more info in the April 2006 issue of Pharm Exec.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.